CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5,020 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03131362
NCT03131362N/ACompleted

REALizing and Improving Management of Stable COPD in China--A Multi-centre, Prospective, Observational Study to Realize the Current Situation of COPD Patients in China.

AstraZeneca·observational·Posted Apr 27, 2017·Updated Jan 26, 2022

In Brief

An observational study for Chronic Obstructive Pulmonary Disease COPD. Completed, enrolled 5,020 participants across 1 site.

Detailed Summary

This is a multi-centre, prospective, observational study to realize the current situation of COPD patients in China. About 5000 COPD patients will be enrolled from 50 participating sites around China and followed up for one year. During this study, patients will undergo clinical assessments and receive medical care as determined by their treating physician.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedApr 27, 2017
Enrollment StartJun 30, 2017
Primary CompletionAug 6, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.2 years ago